2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3399 A Phase I study of the allosteric sting agonist CRD3874 for relapsed and refractory acute myeloid leukemia: Trial in progress

Leora Boussi, MD, Andriy Derkach, PhD2, Monali Banerjee3, Reinhard von Roemeling4, Ritesh Shrivastava5, Sandip Middya6, Debjani Chakraborty7, Arjun Surya8, Gabrielle Melamed9, Marianne Kenneally10, Christine Moon11, Chandni Dave12, Aaron D Goldberg, MD, PhD13, Sheng F. Cai, MD, PhD14, Eytan M Stein I, MD15
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Curadev Pharma, Noida, India
4 Curadev Pharma, Boston, United States
5 Curadev Pharma, Noida, India
6 Curadev Pharma, Noida, India
7 Curadev Pharma, Noida, India
8 Curadev Pharma, Noida, India
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States

Background and Significance: The Stimulator of Interferon Genes (STING) protein is a key activator of innate immunity and inflammation in response to DNA damage that plays a critical role in anti-tumor immunity. STING is activated by aberrant DNA accumulation in the cytosol and mediates type I interferon (IFN-I) activation leading to tumor-specific T-cell responses (Motwani, Nat Rev Genet 2019). STING also generates non-IFN responses through its proton channel activity (Liu, Science 2023). Additionally, STING upregulates pro-apoptotic gene expression and drives malignant cell death (Diepstraten, Cancer Cell 2024). Impaired STING activation has been implicated in multiple cancers in promoting immune evasion by malignant cells. In preclinical models, acute myeloid leukemia (AML) fails to induce a host IFN-I response, suggesting an impaired capacity to sense disseminated leukemia and associated DNA damage (Curran, Cell Rep 2016). Given aberrant innate immune activation in AML, targeting STING to promote immune activation represents a promising immunotherapeutic approach in relapsed and refractory (RR) AML.

STING agonists exhibit strong anti-tumor immune activity in disseminated AML mouse models, leading to increased cytokine transcriptional activation, promotion of cytotoxic AML-specific T-cell responses, increased expression of pro-apoptotic machinery, and disruption of leukemogenesis with prolonged survival (Diepstraten, Cancer Cell 2024; Curran, Cell Rep 2016; Aikins, J Control Release 2024). Notably, STING-induced activation of the DNA damage response and apoptotic pathway is p53-independent, and STING agonists can potentially overcome TP53 loss and promote cytotoxicity in leukemia cells (Diepstraten, Cancer Cell 2024). Therefore, STING agonism may have therapeutic potential in the context of TP53-mutant AML, which is enriched in the RR setting and confers resistance to standard therapies with poor survival outcomes.

The clinical impact of STING agonists and their role in modulating expression of cytokines and pro-apoptotic proteins have yet to be investigated in AML patients. CRD3874-SI is a novel first-in-class allosteric STING agonist developed for IV administration that blocks STING’s proton channel activity thus distinguishing it from other clinically tested STING agonists. CRD3874-SI promotes leukemic cell death and synergizes with BCL-2 inhibitors in vitro and prolongs survival in preclinical models of AML.

Study Design and Methods: This is a single center, phase 1, investigator-initiated study evaluating CRD3874-SI in patients with RR AML. We hypothesize that CRD3874-SI will be well-tolerated with an acceptable safety profile. Key eligibility criteria include age ≥18 years and RR AML, and major exclusion criteria include history or evidence of symptomatic autoimmune disease and evidence of clinically significant immunosuppression such as primary immunodeficiency state, concurrent opportunistic infection, and systemic immunosuppressive therapy.

The study consists of dose-finding and expansion cohorts. The dose-finding portion of the study utilizes a 3+3 dose-escalation design to determine the pharmacokinetics, pharmacodynamics, safety, and tolerability of CRD3874-SI in patients with RR AML to inform the recommended phase 2 dose (RP2D). There are 4 planned dose levels of CRD3874-SI: 0.6 mg/kg, 0.9 mg/kg, 1.4 mg/kg, and a back-up dose of 0.3 mg/kg. Cycles will be 28 days long, and patients will receive CRD3874-SI intravenously once weekly on days 1, 8, 15 and 22 of each cycle. The window for monitoring dose-limiting toxicity (DLT) will consist of the first cycle. After the RP2D is established, up to 6 patients will be enrolled in the expansion cohort to be treated at the RP2D, with up to 24 patients total enrolled in the study depending on the toxicity profile observed.

The primary endpoint is the maximum tolerated dose (MTD) and RP2D. Secondary endpoints include frequency, duration, and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs). Exploratory endpoints include composite complete remission (cCR) rate including CR, CR with incomplete count recovery (CRi), and CR with partial hematologic recovery (CRh), as well as minimal residual disease (MRD)-negative remissions assessed by multiparameter flow cytometry.

The study is funded, IRB-approved and actively accruing patients (NCT07661095). First patient accrual occurred in June 2026.

Leora Boussi, MD: No relevant conflicts of interest to declare.